BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29

BridgeBio Pharma, Inc.

2024-Q2 EPS reported -$0.59 revenue$213,288,000

Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.
Acoramidis NDA for ATTR-CM accepted; PDUFA date Nov 29, 2024; 42% reduction in composite CVH and ACM events at Month 30.
Cash, equivalents, marketable securities and short-term restricted cash $587.2M as of June 30, up from $392.6M at Dec 31, 2023.
Phase 3 FORTIFY study (BBP-418 for LGMD2I/R9) surpassed interim analysis enrollment target; top-line data expected 2025.
Infigratinib in achondroplasia: +2.50 cm/yr annualized height velocity at Month 18 (p=0.0015), significant body proportionality improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.